



Comparison of health effects following oral exposures to PFOA and HFPO-DA (GenX) in pregnant mice

**Sue Fenton, PhD
NTP Laboratory
DNTP/NIEHS**

**Research Triangle Environmental Health Collaborative
October 23, 2019**



Developmental PFOA Exposure Sensitive Targets

- **Fetal development**
 - Birth weight decrements in humans and mice
- **Adipose**
 - Overweight if developmentally exposed
 - Insulin and glucose tolerance
 - Hines et al, 2009, *Mol. Cell Endocrinol.*
- **Breast/Mammary gland**
 - Decreased breastfeeding duration/efficiency/ability in women and mice
 - Mammary developmental delays with no change in other pubertal timepoints (in studies that have evaluated this tissue) – permanent change in those studies that have evaluated latent effects
- **Liver**
 - Hepatocellular hypertrophy, lipid deposition, enlarged relative liver weight
 - Liver disease (altered enzyme levels, cancer, etc)
 - Increased mitochondrial number in developmentally exposed mice



Photo from *Environ Health Perspect Focus*



Focused research projects under REACT:

Responsive Evaluation and Assessment of Chemical Toxicity

Primary goals:


Using mice, compare GenX* to PFOA on already established sensitive endpoints

- *Evaluate effects on fetal weight gain (PFOA Navigation Guide)*
- *Determine effects on metabolic end points and weight gain*
- *Examine puberty timing and mammary endpoints (dam and pup)*
- *Examine adult and developing liver for pathology and mechanisms*
- *Establish relationship(s) between histopathology and other end points*
- *Understand internal dose and transfer to offspring*


*PFOA (Perfluorooctanoic acid ammonium salt, CAS# 3825-26-1) and GenX (Hexafluoropropylene Oxide Dimer Acid or [Ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propanoate], CAS# 62037-80-3)



Adverse Pregnancy Outcomes



Evaluate PFOA concurrently with its replacement compound, GenX, for adverse effects on the maternal-placental-embryo unit in a mouse model





Study design and experimental methods

Treatment Groups N = 11-13 dams

Control (water)

1 mg/kg/day PFOA

5 mg/kg/day PFOA

2 mg/kg/day GenX

10 mg/kg/day GenX


Drinking Water Standards

PFOA	70 ppt (US EPA)
GenX	140 ppt (NC DHHS/DEQ)

- PFOA doses: selected based on previous studies
- GenX doses: selected to serve as "equivalent" doses



Clinical Chemistry,
Histology & Transmission
Electron Microscopy
(TEM)
Cellular & Molecular
Pathology Branch
NIEHS





GenX and PFOA Disposition

Treatment Groups N = 11-13 dams

Control (water)

1 mg/kg/day PFOA

5 mg/kg/day PFOA

2 mg/kg/day GenX

10 mg/kg/day GenX

Drinking Water Standards

PFOA	70 ppt (US EPA)
GenX	140 ppt (NC DHHS/DEQ)

- PFOA doses: selected based on previous studies
- GenX doses: selected to serve as "equivalent" doses



Plug +
E0.5 E1.5




Acclimation
Daily weight & dosing
Daily weight & dosing

E11.5

Sacrifice

E17.5

Sacrifice






GenX and PFOA affect liver

100% of livers from dams exposed to PFOA (1 or 5 mg/kg) or GenX (2 or 10 mg/kg) showed some degree of cytoplasmic alteration

Normal liver histology & TEM at E17.5



Centrilobular hepatocellular hypertrophy with karyomegaly, increased basophilic granular cytoplasm and decreased glycogen












Arrows: prominent rough endoplasmic reticulum with abundant ribosomes

Asterisks: evenly dispersed, abundant glycogen

Nu = nucleolus
N = nucleus
K = Kupffer cell
* = glycogen
P = peroxisomes
M = mitochondria
V = vacuole





Representative images of pathology induced by PFOA or GenX at E17.5



Blake *et al* 2019, under review



GenX and PFOA affect liver




Transmission electron microscopy (TEM) of liver from a control (left) and 10mg/kg/day GenX treated pregnant dam at gestation day 17.5. Note the abundance of mitochondria (M), increased vacuolation, altered rough endoplasmic reticulum (arrows) and depletion of glycogen (asterisks) in treated liver. P = peroxisomes, N = nucleus.



Liver levels of GenX and PFOA

GenX induces similar adverse maternal liver pathology as PFOA at internal liver concentrations ~10x lower






Placenta is a sensitive target of both PFOA and GenX

E17.5 estimates and 95% CI

	Fetal weight (g)	Placental weight (mg)	Fetal:Placental weight ratio
Vehicle Control	1378.6 (1206.3, 1550.8)	130.8 (109.8, 151.8)	11.2 (9.2, 13.3)
1 mg/kg PFOA	1350.7 (1091.9, 1609.4)	129.7 (98.2, 161.2)	11.1 (8.0, 14.3)
5 mg/kg PFOA	↓ 1249.5 (991.0, 1508.0)*	↑ 151.9 (120.5, 183.4)*	↓ 8.5 (5.4, 11.6)*
2 mg/kg GenX	1369.8 (1111.3, 1628.4)	137.1 (105.6, 168.6)	10.6 (7.5, 13.7)
10 mg/kg GenX	1337.0 (1077.5, 1596.4)	↑ 146.3 (114.7, 177.9)*	↓ 9.5 (6.4, 12.7)*



*Beta estimate 95% confidence intervals do not overlap zero (Mixed effect model adjusting *a priori* for litter size as fixed effect and the dam as random effect); N = 11-13 dams with 62-80 observations per group




Mixed effect models fit using likelihood ratio test; model estimates with 95% CI
 N = 11-13 litters with 1-3 observations per litter



Congener-specific placental lesion profiles



Incidence of Placental Lesions





- **Similar effects of PFOA and GenX in liver, with lower GenX burden in liver**
- **Unique placental effects, and difference in response for fetal growth**
- **No sex specific differences in fetal burden of PFOA or GenX**
- **Mammary gland of offspring – sex specific effects**
 - **Pup mammary effects at 1 mg/kg GenX and 0.1 mg/kg PFOA**
- **Ongoing work addressing maternal mammary gland development, metabolic effects in offspring and other reproductive tissues in pups**
- **PFOA and GenX-induced transcriptomic pathways that are shared and unique in placenta, liver, and mammary tissue are being determined**
- **Future studies to address lower doses and adverse outcome pathways**

Acknowledgements

Collaborators

US EPA National Exposure Research Laboratory

Mark Strynar, PhD

James McCord, PhD

Duke University

Heather Stapleton, PhD

Samantha Hall

NIEHS Cellular & Molecular Pathology Branch

Susan Elmore, PhD

Dave Malarkey, PhD DACVP

NIEHS Mouse Embryo Phenotyping Core

Beth Mahler

Brittany Scott

NIEHS Clinical Pathology Group

Debra King

Ralph Wilson

The Fenton Lab

BEVIN BLAKE

HARLIE COPE

CHARLOTTE LOVE

Vesna Chappell, PhD



Funding

T32 training grant ES007126

NIEHS NTP funded

TEM of Liver:

Robert Keys, PhD

NIEHS Biostatistics & Computational Biology Branch

Keith Shockley, PhD

NIEHS Fluorescence Microscopy and Imaging Center

Jeff Tucker, PhD